Earnings ·
Gilead Sciences reported second quarter 2026 total revenues of $7.8 billion, a 10% increase year-over-year, driven by…
GILDGilead Sciences, Inc.
Gilead Sciences reported second quarter 2026 total revenues of $7.8 billion, a 10% increase year-over-year, driven by HIV product sales growth of 12% and strength in Trodelvy and Livdelzi. Biktarvy sales rose 7% to $3.8 billion, while Descovy sales surged 48% to $967 million. The company reported a diluted loss per share of $(8.45), primarily due to $11.2 billion in acquired in-process research and development expenses from the Arcellx, Tubulis, and Ouro Medicines acquisitions. Gilead updated its full year 2026 guidance, raising product sales expectations to $30.1–$30.4 billion but lowering diluted loss per share estimates to $(3.75)–$(3.40). The Board declared a quarterly dividend of $0.82 per share for the third quarter of 2026, payable on September 29, 2026, to shareholders of record as of September 15, 2026. Gilead Sciences is a biopharmaceutical company focused on HIV, viral hepatitis, oncology, and inflammation treatments.